BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

...100 million doses of vaccine in 2021. Valneva...
...and Drug Administration (FDA) Regeneron Pharmaceuticals Inc. University of Oxford Valneva...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...retiring. Aradhye was EVP and chief development officer of Axcella Health Inc. (NASDAQ:AXLA). Vaccine company Valneva...
...see “Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

...NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE); 60 million doses of an inactivated whole virus vaccine from Valneva...
BioCentury | Jul 21, 2020
Product Development

As U.K. secures access to two more vaccines, task force Chair Bingham says more to come

...Vaccine Taskforce Chair Kate Bingham says supply agreements for U.K. access to COVID-19 vaccines from Valneva...
...and up to 1.3 billion additional doses by the end of 2021. The deal with Valneva...
...studies of VLA2001 as well as funding to expand the biotech’s manufacturing facilities in Scotland. Valneva...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...Preparedness Innovations (CEPI). Its partners include the University of Queensland, Sichuan Clover Biopharmaceuticals Inc. and Valneva...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...gets $130M up front in Lyme disease vaccine deal Pfizer Inc. (NYSE:PFE) will collaborate with Valneva...
...to develop VLA15, the biotech’s vaccine candidate for Lyme disease. In a deal announced Thursday, Valneva...
...is in Phase II testing, is the only vaccine for Lyme disease now in development. Valneva...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Therapeutics Inc. (NASDAQ:LOGC) and serves on the boards of Retrophin Inc. (NASDAQ:RTRX), ViaCyte Inc. and Valneva...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...sufficiently predictive of later effectiveness,” said Thomas Lingelbach, president, chairman and CEO of vaccine company Valneva...
...Valneva SE (Euronext:VLA), Lyon, France Erin McCallister, Senior Editor Alkahest Inc. Arrowhead Pharmaceuticals Inc. ImmusanT Inc. Orchard Therapeutics Pluristem Therapeutics Inc. ProQR Therapeutics Valneva...
BioCentury | Apr 13, 2018
Clinical News

Valneva reports Phase I data for Lyme disease vaccine candidate

...a hexavalent recombinant Borrelia outer surface protein A (ospA) vaccine. On the secondary immunogenicity endpoint, Valneva...
...Final safety and immunogenicity data, including one year follow-up data, are expected in early 2019. Valneva...
...II testing of the vaccine in 2H18. VLA15 has Fast Track designation in the U.S. Valneva...
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...JV between Seek Ltd. and hVIVO plc (LSE:HVO); (B) EB66 cell culture technology licensed from Valneva...
Items per page:
1 - 10 of 88